With a solid bench strength possessing expertise across the technical and scientific arenas, Simmons & Simmons is well-positioned to undertake complex and global mandates for clients operating within the life sciences, fintech, and technology sectors. European Patent Attorney Kevin Cordina leads the group with his expertise in electronics and medical devices, and Michael Gavey is well-versed in transactional mandates. On the litigation side, Michael Burdon is noted for his strategic capabilities and Scott Parker routinely acts for pharmaceutical and biotech companies. Angus McLean co-leads the firm's Emerging Technology Group, and Andrew Hutchinson covers a diverse range of patent litigation and regulatory issues. Further strengthening the practice is Priya Nagpal, who enjoys a wealth of experience across technologies such as medical devices and software, and she also possesses expertise in big data issues.
Legal 500 Editorial commentary
- Profile
- Social
Testimonials
Collated independently by Legal 500 research team.
‘The Simmons & Simmons team is highly knowledgeable of our industry and provide prompt and practical advice. They are always available on short notice, easy to work with and high performing.'
‘Michael Burdon has been a steady and trusted partner through a significant patent dispute.'
Key clients
- Boston Scientific Corp
- Boston Scientific Corporation
- Samsung Bioepis
- Apple
- GSK
- Amgen
- AstraZeneca
- Merck Sharp & Dohme
- J&J
- Alnylam
Work highlights
- Represented Boston Scientific in a dispute with Cook Medical spanning the US, USPTO, Germany, EPO, and the Netherlands.
- Advised GSK, Amgen/DeCode, AstraZeneca, Merck Sharp & Dohme, Johnson & Johnson, Alnylam, Pfizer, Biogen, Boehringer Ingelheim, Novo Nordisk, Novartis, Randox, Roche, and Regeneron on a long term £multi-million collaboration agreement with Our Future Health, the UK’s biggest ever health data project design to find new ways to prevent, detect, and treat diseases.
- Advised Samsung Bioepis on the UK patent revocation action and broader European strategy concerning pre-filled syringes of Lucentis/ranibizumab, a blockbuster intraocular drug.
Lawyers
Practice head
Kevin Cordina
Other key lawyers
Michael Gavey; Michael Burdon; Scott Parker; Angus McLean; Andrew Hutchinson; Priya Nagpal